This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Among prokaryotes, five major groups of bacteria have evolved the ability to photosynthesize, including heliobacteria, green sulfur and nonsulfur bacteria and proteobacteria. However, the only lineage where oxygenic photosynthesis has evolved is in the cyanobacteria, often known as blue-green algae for their blue-green (cyan) coloration. They are classified as the phylum Cyanobacteriota or Cyanophyta. However, this phylum also includes two classes of non-photosynthetic bacteria: Melainabacteria (also called Vampirovibrionia or Vampirovibrionophyceae) and Sericytochromatia (also known as Blackallbacteria). A third class contains the photosynthetic ones, known as Cyanophyceae (also called Cyanobacteriia or Oxyphotobacteria). As bacteria, their cells lack membrane-bound organelles, with the exception of thylakoids. Like other algae, cyanobacteria have chlorophyll a as their primary photosynthetic pigment. Their accessory pigments include phycobilins (phycoerythrobilin and phycocyanobilin), carotenoids and, in some cases, b, d, or f chlorophylls, generally distributed in phycobilisomes found in the surface of thylakoids. They display a variety of body forms, such as single cells, colonies, and unbranched or branched filaments. Their cells are commonly covered in a sheath of mucilage, and they also have a typical gram-negative bacterial cell wall composed largely of peptidoglycan. They have various storage particles, including cyanophycin as aminoacid and nitrogen reserves, "cyanophycean starch" (similar to plant amylose) for carbohydrates, and lipid droplets.
== The Bakery restaurant == Operating from 1963 to 1989, Szathmary's Chicago restaurant, The Bakery, served what Szathmary referred to as "continental dishes with American undertones". The inclusion of "exotic" European dishes expanded the fine dining in Chicago and made The Bakery a popular destination. The individual beef Wellington was particularly famous, and heavily cited on Chicago diners' must-try lists. Within its first year of operation, more than 200 articles were written about The Bakery. The restaurant attracted guests internationally, and Szathmary hosted parties for Hugh Hefner, Frank Zappa, and conductor Arthur Fiedler.
== Therapeutic approaches and pharmacology == Therapeutic approaches for IRAP regulation rely on the development of peptidomimetics and small molecule inhibitors. The most explored classes of inhibitors for IRAP are the catalytic or the allosteric site ones.
Hemoglobin, for comparison, has a Hill coefficient of usually 2.8–3.0. In these cases of cooperative binding hemocyanin was arranged in protein sub-complexes of 6 subunits (hexamer) each with one oxygen binding site; binding of oxygen on one unit in the complex would increase the affinity of the neighboring units. Each hexamer complex was arranged together to form a larger complex of dozens of hexamers. In one study, cooperative binding was found to be dependent on hexamers being arranged together in the larger complex, suggesting cooperative binding between hexamers. Hemocyanin oxygen-binding profile is also affected by dissolved salt ion levels and pH. Hemocyanin is made of many individual subunit proteins, each of which contains two copper atoms and can bind one oxygen molecule (O2). Each subunit weighs about 75 kilodaltons (kDa). Subunits may be arranged in dimers or hexamers depending on species; the dimer or hexamer complex is likewise arranged in chains or clusters with weights exceeding 1500 kDa. The subunits are usually homogeneous, or heterogeneous with two variant subunit types. Because of the large size of hemocyanin, it is usually found free-floating in the blood, unlike hemoglobin.
=== Environment === Boosting natural resource efficiency is the "single most important need for a sustainable food future," according to the World Resource Institute. As mentioned in the on-farm efficiency section, precision farming, including variable rate nutrient application, variable rate irrigation, machine guidance, and variable rate planting/seeding, could minimize use of agricultural inputs for a given yield. This could mitigate resource waste and negative environmental externalities, like greenhouse gas (GHG) emissions, soil erosion, and fertilizer runoff. For example, Katalin et al. 2014 estimate that switching to precision weed management could save up to 30,000 tons of pesticide in the EU-25 countries. González-Dugo et al. 2013 found that precision irrigation of a citrus orchard could reduce water use by 25 percent while maintaining a constant yield. Basso et al. 2012 demonstrated that variable-rate application of fertilizer can reduce nitrogen application and leaching without affecting yield and net return. However, precision agriculture could also accelerate farms' depletion of natural resources because of a rebound effect; increasing input efficiency does not necessarily lead to resource conservation.
Sources: en.wikipedia.org
acronym = an abbreviation pronounced as if it were a word, e.g., SARS = severe acute respiratory syndrome, pronounced to rhyme with cars initialism = an abbreviation pronounced wholly or partly using the names of its constituent letters, e.g., CD = compact disc, pronounced cee dee pseudo-blend = an abbreviation whose extra or omitted letters mean that it cannot stand as a true acronym, initialism, or portmanteau (a word formed by combining two or more words). (a) = acronym, e.g.: SARS – (a) severe acute respiratory syndrome (i) = initialism, e.g.: CD – (i) compact disc (p) = pseudo-blend, e.g.: UNIFEM – (p) United Nations Development Fund for Women (s) = symbol (none of the above, representing and pronounced as something else; for example: MHz – megahertz) Some terms are spoken as either acronym or initialism, e.g., VoIP, pronounced both as voyp and V-O-I-P. (Main list of acronyms)
Therefore, delayed haemolytic reaction does not manifest until after 24 hours when enough antibodies are available to cause a reaction. The red blood cells are removed by macrophages from the blood circulation into liver and spleen to be destroyed, which leads to extravascular haemolysis. This process usually mediated by anti-Rh and anti-Kidd antibodies. However, this type of transfusion reaction is less severe when compared to acute haemolytic transfusion reaction. Febrile nonhemolytic reactions are, along with allergic transfusion reactions, the most common type of blood transfusion reaction and occur because of the release of inflammatory chemical signals released by white blood cells in stored donor blood or attack on donor's white blood cells by recipient's antibodies. This type of reaction occurs in about 7% of transfusions. Fever is generally short lived and is treated with antipyretics, and transfusions may be finished as long as an acute hemolytic reaction is excluded. This is a reason for the now-widespread use of leukoreduction – the filtration of donor white cells from red cell product units. Allergic transfusion reactions are caused by IgE anti-allergen antibodies. When antibodies are bound to its antigens, histamine is released from mast cells and basophils. Either IgE antibodies from the donor's or recipient's side can cause the allergic reaction. It is more common in patients who have allergic conditions such as hay fever.
CMT can also be produced by X-linked mutations, in which case it is called X-linked CMT (CMTX). In CMTX, mutated connexons create nonfunctional gap junctions that interrupt molecular exchange and signal transport. The mutation can appear in the GJB1 gene coding for the connexin 32 protein, a gap junction protein expressed in Schwann cells. Because this protein is also present in oligodendrocytes, demyelination can appear in the CNS as well. Schwann cells create the myelin sheath by wrapping their plasma membranes around the axon. These Schwann cells work together with neurons and fibroblasts to create a functional nerve. Schwann cells and neurons exchange molecular signals by way of gap junctions that regulate survival and differentiation. Demyelinating Schwann cells cause abnormal axon structure and function. They may cause axon degeneration, or they may simply cause axons to malfunction. The myelin sheath allows nerve cells to conduct signals faster. When the myelin sheath is damaged, however, nerve signals are slower. This can be measured by a common neurological test, electromyography. When the axon is damaged, the result is a reduced compound muscle action potential.
General Public were an English new wave band, formed in Birmingham in 1983, by vocalists Dave Wakeling and Ranking Roger of the Beat, and which also included former members of Dexys Midnight Runners, the Specials, and the Clash. They are best remembered for their hits "Tenderness" (1984) and "I'll Take You There" (1994).
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.